About Biophytis
Biophytis is a company based in Romainville (France) founded in 2006. Biophytis has raised $2.6 million across 6 funding rounds from investors including Seventure Partners and CM-CIC Capital Prive. The company has 20 employees as of December 31, 2024. Biophytis offers products and services including BIO101 and Macuneos (BIO201). Biophytis operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Biological E, Vir Biotechnology and Neurocrine, among others.
- Headquarter Romainville, France
- Employees 20 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biophytis Sa
-
Annual Revenue
Not available
-
Net Profit
-$10.78 M (USD)39.04as on Dec 31, 2024
-
EBITDA
-$9.71 M (USD)38.02as on Dec 31, 2024
-
Total Equity Funding
$2.6 M (USD)
in 6 rounds
-
Latest Funding Round
$1.58 M (USD), Post-IPO
Mar 13, 2026
-
Investors
Seventure Partners
& 1 more
-
Employee Count
20
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Biophytis
Biophytis is a publicly listed company on the EURONEXT with ticker symbol ALBPS in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Biophytis
Biophytis offers a comprehensive portfolio of products and services, including BIO101 and Macuneos (BIO201).
Oral molecule for treating sarcopenia and neuromuscular conditions.
Oral treatment for retinal diseases like macular degeneration.
People of Biophytis
Unlock access to complete
Unlock access to complete
Funding Insights of Biophytis
Biophytis has successfully raised a total of $2.6M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.58 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biophytis
Biophytis has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Seventure Partners and CM-CIC Capital Prive.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US
|
Locked | Locked | Locked | |
|
Private equity firm focused on SMEs
|
Locked | Locked | Locked |
Investor details for Biophytis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biophytis
Investment portfolio details for Biophytis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Biophytis
Detailed financials for Biophytis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biophytis Comparisons
Peer comparison for Biophytis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biophytis
Biophytis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Biological E, Vir Biotechnology and Neurocrine, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of infectious diseases
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
Detailed competitors of Biophytis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biophytis
Complete news archive for Biophytis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biophytis
Biophytis was founded in 2006 and raised its 1st funding round 6 years after it was founded.
Biophytis is headquartered in Romainville, France. It is registered at Romainville, Ile-de-france, France.
Biophytis is a funded company, having raised a total of $2.6M across 6 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Biophytis is 20.
The company was founded in 2006 and is headquartered in Romainville, France. Focus is placed on the biotechnology sector, where treatments for neuromuscular and age-related conditions are developed. Sarconeos (BIO101), an oral small molecule, is advanced for sarcopenia and Duchenne muscular dystrophy. Macuneos (BIO201) is pursued for retinal disorders such as dry age-related macular degeneration and Stargardt disease. Operations center on clinical-stage drug candidates.
Biophytis's top competitors include Jazz Pharmaceuticals, Vaxcyte and PTC Therapeutics.
Biophytis offers BIO101 and Macuneos (BIO201).
Yes, Biophytis is publicly traded on EURONEXT under the ticker symbol ALBPS.
Biophytis has 2 investors. Key investors include Seventure Partners, and CM-CIC Capital Prive.
The ticker symbol of Biophytis is ALBPS on EURONEXT.